吃绥美凯要注意什么事项

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation Trimeq (dote abalamib tablets) with the new generation integrase inhibitor dolutegravir (DTG) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Today, let’s learn more about what should we pay attention to when taking Suimeikai (Doteta abalami tablets)?

Precautions for using Suimeikan (dolute abalamib tablets) are not clear. Patients should consult a physician or pharmacist in detail before taking medication and strictly follow the physician's recommendations.

Suimeike (Dolutea Paramide Tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

Transmitting HIV Although effective viral suppression with antiretroviral treatment has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be ruled out. Precautions should be taken to prevent transmission in accordance with national guidance. 

Note for children:

The safety and effectiveness of Suimeikan (doteta abalamide) in children under 12 years of age has not been established. No data yet.

Precautions during pregnancy and lactation:

Pregnancy In general, animal data as well as clinical experience in pregnant women should be considered when deciding to use antiretroviral drugs to treat HIV infection in pregnant women to reduce the risk of vertical transmission of HIV to the newborn. There are no data on the use of Trimax (doteta abalamide) in pregnant women. Data on the use of dolutegravir in pregnant women are limited or non-existent. The effects of dolutegravir on human pregnancy are unknown. Regarding the coadministration of abacavir and lamivudine in pregnant women, there is a limited amount of data indicating no teratogenic toxicity (more than 400 results from first-trimester exposure). See the instructions for the rest of the details.

Note for the elderly:

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Trimax in this age group.

The above is the content of the precautions for Suimeikai (Doteta Abalamid Tablets). I hope it can help you!